• Something wrong with this record ?

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

M. Sobas, W. Knopinska-Posluszny, B. Piątkowska-Jakubas, F. García-Álvarez, MEA. Díez, M. Caballero, D. Martínez-Cuadrón, E. Aguiar, J. González-Campos, A. Garrido, L. Algarra, O. Salamero, J. de la Serna, MJ. Sayas, MM. Perez-Encinas, S. Vives,...

. 2024 ; 103 (2) : 451-461. [pub] 20231219

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007339

The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA "chemotherapy based" and "chemotherapy free" protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8-231.1): 43.3 (range: 2.8-113.9) for s-MDS/AML and 61.7 (range: 7.1-231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584; p < 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09; p = 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.

Centro Hospitalar Săo Joăo Porto Portugal

Collegium Medicum Jagiellonian University Krakow Poland

Department of Hematology and Transplantology Gdynia Poland

Department of Hematology Blood Neoplasm and Bone Marrow Transplantation Wroclaw Medical University Wroclaw Poland

Department of Hematology Research Unit Hospital Universitario de Burgos Facultad de Ciencias de la Salud Universidad Isabel 1 Burgos Spain

Department of Mathematics and Computer Science Eindhoven University of Technology 5612 AZ Eindhoven The Netherlands

Faculty of Pure and Applied Mathematics Wrocław University of Science and Technology Wroclaw Poland

Hospital 12 de Octubre Madrid Spain

Hospital Central de Asturias Oviedo Spain

Hospital Clínico San Carlos Madrid Spain

Hospital de Cruces Barakaldo Spain

Hospital de Santa Maria Lisboa Portugal

Hospital Dr Peset Valencia Spain

Hospital General de Albacete Albacete Spain

Hospital Insular de Las Palmas Las Palmas de Gran Canaria Spain

Hospital Maciel Montevideo Uruguay

Hospital Morales Meseguer Murcia Spain

Hospital Puerta de Hierro Madrid Spain

Hospital San Pedro de Alcántara Caceres Spain

Hospital Sant Pau Barcelona Spain

Hospital Tornú Buenos Aires Argentina

Hospital U Germans Trias i Pujol ICO Badalona Spain

Hospital U Vall D'Hebron Barcelona Spain

Hospital U Virgen del Rocio Sevilla Spain

Hospital Universitario de Gran Canaria Doctor Negrin Las Palmas de Gran Canaria Spain

Hospital Universitario i Politècnico la Fe Valencia Spain

Medical University of Lodz Lodz Poland

Rydygiera Hospital Torun Poland

University Hospital Brno Masaryk University Brno Czechia

University Hospital of Salamanca Salamanca Spain

University Hospital Santiago de Compostela Spain

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007339
003      
CZ-PrNML
005      
20240423155904.0
007      
ta
008      
240412s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-023-05582-y $2 doi
035    __
$a (PubMed)38110588
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Sobas, Marta $u Department of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. marta.sobas@umw.edu.pl $1 https://orcid.org/0000000307818668
245    10
$a Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience / $c M. Sobas, W. Knopinska-Posluszny, B. Piątkowska-Jakubas, F. García-Álvarez, MEA. Díez, M. Caballero, D. Martínez-Cuadrón, E. Aguiar, J. González-Campos, A. Garrido, L. Algarra, O. Salamero, J. de la Serna, MJ. Sayas, MM. Perez-Encinas, S. Vives, B. Vidriales, J. Labrador, AI. Prado, L. Celebrin, J. Mayer, J. Brioso, A. de Laiglesia, JM. Bergua, ML. Amigo, C. Rodriguez-Medina, M. Polo, A. Pluta, E. Cichocka, M. Skarupski, MA. Sanz, A. Wierzbowska, P. Montesinos
520    9_
$a The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA "chemotherapy based" and "chemotherapy free" protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8-231.1): 43.3 (range: 2.8-113.9) for s-MDS/AML and 61.7 (range: 7.1-231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584; p < 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09; p = 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    12
$a akutní promyelocytární leukemie $x diagnóza $x farmakoterapie $x epidemiologie $7 D015473
650    _2
$a tretinoin $7 D014212
650    12
$a sekundární malignity $x farmakoterapie $7 D016609
650    _2
$a incidence $7 D015994
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a rizikové faktory $7 D012307
650    _2
$a patologická kompletní odpověď $7 D000095384
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
655    _2
$a časopisecké články $7 D016428
700    1_
$a Knopinska-Posluszny, Wanda $u Department of Hematology and Transplantology, Gdynia, Poland
700    1_
$a Piątkowska-Jakubas, Beata $u Collegium Medicum Jagiellonian University, Krakow, Poland
700    1_
$a García-Álvarez, Flor $u Hospital Central de Asturias, Oviedo, Spain
700    1_
$a Díez, María Elena Amutio $u Hospital de Cruces, Barakaldo, Spain
700    1_
$a Caballero, Mar $u Hospital Insular de Las Palmas, Las Palmas de Gran Canaria, Spain
700    1_
$a Martínez-Cuadrón, David $u Hospital Universitario i Politècnico la Fe, Valencia, Spain
700    1_
$a Aguiar, Eliana $u Centro Hospitalar Săo Joăo, Porto, Portugal
700    1_
$a González-Campos, Jose $u Hospital U. Virgen del Rocio, Sevilla, Spain
700    1_
$a Garrido, Ana $u Hospital Sant Pau, Barcelona, Spain
700    1_
$a Algarra, Lorenzo $u Hospital General de Albacete, Albacete, Spain
700    1_
$a Salamero, Olga $u Hospital U. Vall D'Hebron, Barcelona, Spain
700    1_
$a de la Serna, Javier $u Hospital 12 de Octubre, Madrid, Spain
700    1_
$a Sayas, Maria Jose $u Hospital Dr. Peset, Valencia, Spain
700    1_
$a Perez-Encinas, Manuel Mateo $u University Hospital, Santiago de Compostela, Spain
700    1_
$a Vives, Susana $u Hospital U. Germans Trias i Pujol ICO, Badalona, Spain
700    1_
$a Vidriales, Belén $u University Hospital of Salamanca (CAUSA/IBSAL) and Center for Biomedical Research in Network of Cancer (CIBERONC), Salamanca, Spain
700    1_
$a Labrador, Jorge $u Department of Hematology, Research Unit, Hospital Universitario de Burgos, Facultad de Ciencias de la Salud, Universidad Isabel I, Burgos, Spain
700    1_
$a Prado, Ana Inés $u Hospital Maciel, Montevideo, Uruguay
700    1_
$a Celebrin, Lucía $u Hospital Tornú, Buenos Aires, Argentina
700    1_
$a Mayer, Jiri $u University Hospital Brno, Masaryk University, Brno, Czechia
700    1_
$a Brioso, Joana $u Hospital de Santa Maria, Lisboa, Portugal
700    1_
$a de Laiglesia, Almudena $u Hospital Puerta de Hierro, Madrid, Spain
700    1_
$a Bergua, Juan Miguel $u Hospital San Pedro de Alcántara, Caceres, Spain
700    1_
$a Amigo, Maria Luz $u Hospital Morales Meseguer, Murcia, Spain
700    1_
$a Rodriguez-Medina, Carlos $u Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
700    1_
$a Polo, Marta $u Hospital Clínico San Carlos, Madrid, Spain
700    1_
$a Pluta, Agnieszka $u Medical University of Lodz, Lodz, Poland
700    1_
$a Cichocka, Edyta $u Rydygiera Hospital, Torun, Poland
700    1_
$a Skarupski, Marek $u Faculty of Pure and Applied Mathematics, Wrocław University of Science and Technology, Wroclaw, Poland $u Department of Mathematics and Computer Science, Eindhoven University of Technology, 5612, AZ, Eindhoven, The Netherlands
700    1_
$a Sanz, Miguel A $u Hospital Universitario i Politècnico la Fe, Valencia, Spain
700    1_
$a Wierzbowska, Agnieszka $u Medical University of Lodz, Lodz, Poland
700    1_
$a Montesinos, Pau $u Hospital Universitario i Politècnico la Fe, Valencia, Spain
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 103, č. 2 (2024), s. 451-461
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38110588 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155901 $b ABA008
999    __
$a ok $b bmc $g 2081366 $s 1217106
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 103 $c 2 $d 451-461 $e 20231219 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options